Work

Dual PI3K/mTOR inhibition is required to combat resistance to CDK4/6 inhibitor and endocrine therapy in PIK3CA -mutant breast cancer

Year: 2025

Type: article

Source: Science Translational Medicine

DOI: 10.1126/scitranslmed.adp5088

Authors: Carla L. Alves, Leena Karimi, Mikkel G. Terp, Mie K. Jakobsen, Fiona H. Zhou, Benedetta Policastro, Nikoline Nissen, Lene E. Johansen, Tina Ravnsborg, Leila Eshraghi, Sana Tamboowala, Ole N. Jensen, Elgene Lim, Henrik J. Ditzel

Institutions: University of Southern Denmark, Garvan Institute of Medical Research, UNSW Sydney, Odense University Hospital

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Kræftens Bekæmpelse, Novo Nordisk Fonden

Award: G1024401664

OpenAlex ID: W4417439418

FWCI: 4.119

Cites: 61

Cited by: 7

Related to: